News & InsightsNewsletterLegislation Hub

Foresight

Foresight
AboutContactBook DemoLog in
Start free trial
Foresight logo
All News & Insights

EU Launches Public Consultation on Phthalates in Medical Devices

General
2
April 2024
•
350
Dr Steven Brennan
Stakeholders are encouraged to provide feedback on the preliminary guidelines by submitting written comments.
Medical devices
Quick prompts

AI Generated

Get to the point quicker with prompts - a smarter way to get the information you need from our articles.

Summarise this article

AI Assistant

This feature and much more is available on our platform. If you would like early access, please leave your email and we'll get in touch.

We'll be in touch when the Assistant is ready.
Oops! Something went wrong while submitting the form.
Mountains

In a significant step towards addressing public health concerns, the European Union, through the European Commission and its Scientific Committee on Health, Environmental and Emerging Risks (SCHEER), has opened a public consultation on the preliminary update of the SCHEER guidelines. This initiative focuses on the benefit-risk assessment of the presence of phthalates in certain medical devices, particularly those identified as carcinogenic, mutagenic, toxic to reproduction (CMR), or having endocrine-disrupting (ED) properties.

Consultation Details

  • Status: Open
  • Opening Date: 21 March 2024
  • Deadline: 28 April 2024, 23:59 (CEST)
  • Target Audience: Public health community

This consultation is crucial for the advancement of safer medical devices and invites input from all relevant stakeholders, including manufacturers, notified bodies, regulatory entities, and the general public.

Objectives and Scope of the Guidelines

The updated guidelines serve a vital role in ensuring the safety and efficacy of medical devices that contain phthalates with CMR or ED properties. Key aspects of the guidelines include:

  • Evaluation of possible alternatives to phthalates used in medical devices.
  • Methodology for performing a benefit-risk assessment to justify the presence of CMR/ED phthalates in medical devices.
  • Support for assessments of other CMR/ED substances in medical devices.

The initiative underscores the EU's commitment to public health and safety by regulating the use of potentially harmful substances in medical devices. By revising the SCHEER guidelines, the European Commission aims to reflect the latest scientific evidence and promote the development and use of safer alternatives.

How to Participate

Stakeholders are encouraged to provide feedback on the preliminary guidelines by submitting written comments through the designated electronic template by the specified deadline. This process allows for a comprehensive review of the scientific basis of the guidelines and identification of areas requiring further investigation.

SCHEER has reiterated the importance of manufacturers generating high-quality data on alternatives to CMR/ED phthalates in medical devices. Such data are crucial for informed decision-making and the development of safer medical products.

Looking Ahead

The feedback obtained from this consultation will play a pivotal role in shaping the final guidelines, ensuring they effectively address the risks associated with phthalates in medical devices. The European Commission's proactive approach, through SCHEER, highlights the ongoing efforts to enhance public health protections within the EU.

This public consultation represents a collaborative effort to refine regulatory standards and promote the safety of medical devices across Europe. Stakeholders are urged to participate actively in this critical consultation process.

Read the source story

In a significant step towards addressing public health concerns, the European Union, through the European Commission and its Scientific Committee on Health, Environmental and Emerging Risks (SCHEER), has opened a public consultation on the preliminary update of the SCHEER guidelines. This initiative focuses on the benefit-risk assessment of the presence of phthalates in certain medical devices, particularly those identified as carcinogenic, mutagenic, toxic to reproduction (CMR), or having endocrine-disrupting (ED) properties.

Consultation Details

  • Status: Open
  • Opening Date: 21 March 2024
  • Deadline: 28 April 2024, 23:59 (CEST)
  • Target Audience: Public health community

This consultation is crucial for the advancement of safer medical devices and invites input from all relevant stakeholders, including manufacturers, notified bodies, regulatory entities, and the general public.

Read this article now for free!

You have read 3 articles.
Create a free account
or
Log in
to finish reading this article now.

Subscribe to our weekly digest

Sign up to receive our newsletter every Tuesday and get access to all of our content.

By creating an account, you agree to the Terms of Service and Privacy Policy.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
This is some text inside of a div block.

Trusted by professionals at

Dupont
ECHA - European Chemicals Agency
Energizer
Chemours
This is some text inside of a div block.

Get Foresight Today

Stay compliant, reduce risk, and protect your business with our AI-powered chemical policy monitoring—tailored just for you.

Global monitoring of 1,200+ sources
Expert-reviewed, trusted regulatory alerts
Instant risk identification for 350k+ substances

Ready to supercharge your policy monitoring workflow?

We’ll be in touch soon with more details and support to help you get started.
Oops! Something went wrong while submitting the form.
Share with a friend
Copy link

Related Articles

Office meetingGlobal Panel on Chemicals, Waste and Pollution Established to Guide Future Regulation

July 6, 2025

PlantsEU Reopens Glyphosate Carcinogenicity Review, Triggering Regulatory Reassessment

July 6, 2025

Americal Chemistry Council logoACC Reaffirms BPA Safety in Packaging Amid Growing Regulatory Scrutiny

July 6, 2025

Foresight regulatory experts
Streamline your chemical compliance
Easy-to-use product compliance management for small and mid-sized manufacturers — mitigate risk and protect market access.
Get started
Subscribe to Foresight's newsletter
Stay ahead with the latest news & insights
Join 1,000s of compliance professionals getting the latest insights right to their inbox for free, every Tuesday.
100% free. No spam. Unsubscribe any time.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Stay ahead with the latest news & insights
Subscribe to our free weekly newsletter covering news, events, and expert insights.

Related articles

European Parliament

EU Faces Scrutiny Over Inaction on Chemicals Strategy Commitments

A European Parliament report highlights the EU’s failure to deliver key chemicals strategy actions, affecting policy certainty across sectors.

6

Jul 2025

General
Plants

EU Reopens Glyphosate Carcinogenicity Review, Triggering Regulatory Reassessment

The EU has mandated a review of glyphosate’s carcinogenicity, impacting chemical compliance and risk assessments across multiple industries.

6

Jul 2025

General
Fast fashion

France Targets Ultra-Express Fashion with New Regulation to Curb Environmental Impact

France’s new regulation on ultra-express fashion redefines textile compliance by 2026, urging producers and platforms to embrace sustainability.

6

Jul 2025

General
Foresight
Providing critical insights, analysis, and guidance to help businesses anticipate changes, make informed decisions, and stay ahead.
News & Insights
Newsletter
Legislation Hub
Coverage
Contact
About
© 2025 Foresight. All rights reserved.
SitemapTerms of servicePrivacy policyCookie policy